8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Aug 17, 2009)

Filed August 17, 2009For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) filed a Form 8-K on August 17, 2009, primarily to respond to a comment from the Securities and Exchange Commission (SEC) regarding previously filed material agreements. This filing involves key strategic alliances related to significant products: the codevelopment and cocommercialization of PLAVIX® / ISCOVER® (clopidogrel bisulfate) with sanofi-aventis, and ABILIFY® (aripiprazole) with Otsuka Pharmaceutical Co., Ltd. Investors should note that this 8-K does not contain new financial results or material operational updates in terms of performance. Instead, it focuses on the legal and contractual framework supporting these important collaborations. The extensive list of exhibits provides insight into the governance and operational structures of these partnerships, which are crucial for the revenue generation and future growth of BMY through its key drug franchises.

Key Highlights

  • 1BMY filed an 8-K on August 17, 2009, in response to SEC staff comments.
  • 2The filing pertains to material agreements for collaborations on PLAVIX®/ISCOVER® with sanofi-aventis.
  • 3The filing also covers material agreements for the collaboration on ABILIFY® with Otsuka Pharmaceutical Co., Ltd.
  • 4No new financial or operational performance data is presented; the filing is administrative.
  • 5The extensive exhibit list details various agreements related to the PLAVIX® and ABILIFY® partnerships, including amendments and related agreements.
  • 6Some portions of the filed agreements have requested confidential treatment, filed separately with the SEC.
  • 7The filing underscores the ongoing importance of these key drug collaborations to Bristol Myers Squibb's business.

Frequently Asked Questions

The main purpose of this 8-K filing is to provide material agreements related to Bristol Myers Squibb's (BMY) codevelopment and cocommercialization alliances for PLAVIX®/ISCOVER® with sanofi-aventis and ABILIFY® with Otsuka Pharmaceutical Co., Ltd., in response to a comment from the SEC staff.

No, this filing does not contain new financial results or performance updates. It is an administrative filing to provide documentation for existing material agreements as requested by the SEC.

The key products involved are PLAVIX® / ISCOVER® (clopidogrel bisulfate) in the alliance with sanofi-aventis, and ABILIFY® (aripiprazole) in the alliance with Otsuka Pharmaceutical Co., Ltd.

Confidential treatment has been requested for certain portions of the agreements to protect proprietary business information, as is common in significant commercial partnerships. These confidential portions have been filed separately with the SEC.